The impact of previous therapy strategy on the efficiency of anlotinib hydrochloride as a third-line treatment on patients with advanced non-small cell lung cancer (NSCLC): a subgroup analysis of ALTER0303 trial.
Wang L, He Z, Yang S, Tang H, Wu Y, Li S, Han B, Li K, Zhang L, Shi J, Wang Z, Cheng Y, He J, Shi Y, Chen W, Luo Y, Wu L, Wang X, Nan K, Jin F, Dong J, Li B, Sun Y, Wang Q.
Wang L, et al. Among authors: yang s.
Transl Lung Cancer Res. 2019 Oct;8(5):575-583. doi: 10.21037/tlcr.2019.09.21.
Transl Lung Cancer Res. 2019.
PMID: 31737494
Free PMC article.